Dyne Therapeutics said it remains on track to file for approval of its Duchenne muscular dystrophy therapy in 2027, keeping the exon skipping programme on the timeline investors have modelled since its registrational data, the company indicated in its latest update.
Shionogi presented new data on its long acting oral HIV programme, the company’s bid to move treatment from daily pills toward intermittent dosing in a market where injectables have taken the long acting lead.
Medtronic has agreed to acquire Icario, the health action platform, in a deal valued at 875 million dollars according to the company’s announcement, a payer facing asset for a device maker building beyond hardware. Single sourced to the announcement; treat the valuation as company stated.
Readily has raised 11 million dollars to sell compliance software to health insurers, a small round in the least glamorous and most durable corner of health tech, selling to the buyers who cannot opt out of regulation.
The 2.8 billion dollar BlackRock purchase of a majority stake in Humana’s CenterWell clinic business, the week’s largest healthcare transaction, was published here on October 14 and is not repeated in this edition.
On the calendar: Praxis Precision Medicines’ ulixacaltamide for essential tremor has a PDUFA target action date of January 29, 2027, with no advisory committee expected, the next dated FDA catalyst tracked by this beat.